Cargando…

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report

BACKGROUND: To report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution. CASE PRESENTATION: The patient was a 51-year-old woman with no previous history of side effects to ophthalmic antihistamine agents. She had been prescribed alcaftadine 0.2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jae Hyuk, Kim, Hyun Joon, Kim, Sun Woong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657074/ https://www.ncbi.nlm.nih.gov/pubmed/31340775 http://dx.doi.org/10.1186/s12886-019-1166-2

Ejemplares similares

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino, Joseph B, et al.
Publicado: (2015)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

A case report of allergic blepharoconjunctivis to alcaftadine
por: Sandrin, Leda Das Neves Almeida
Publicado: (2015)

Allergic Contact Dermatitis Caused by Topical Eye Drops Containing Latanoprost
por: Lee, Ji Hye, et al.
Publicado: (2014)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Allergic contact dermatitis caused by dorzolamide eyedrops
por: Lee, Seung-Jun, et al.
Publicado: (2015)

Allergic Contact Dermatitis to Eye Drops
por: Bhat, Yasmeen Jabeen, et al.
Publicado: (2015)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

The Fine Scratches of the Spectacle Frames and the Allergic Contact Dermatitis
por: Kim, In Su, et al.
Publicado: (2013)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

Caudal Epidural Analgesia in Pediatric Patients: Comparison of 0.25% Levobupivacaine and 0.25% Ropivacaine in Terms of Motor Blockade and Postoperative Analgesia
por: Praveen, P., et al.
Publicado: (2017)

Bullous Allergic Contact Dermatitis Caused by Potassium Dichromate
por: Navarro-Triviño, Francisco J., et al.
Publicado: (2023)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

A Comparative Study of Effect of 0.25% Levobupivacaine with Dexmedetomidine versus 0.25% Levobupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block
por: Iyer, Lakshmi S., et al.
Publicado: (2021)

Exchange-bias via nanosegregation in novel Fe(2−x)Mn(1+x)Al (x = −0.25, 0, 0.25) Heusler films
por: Kurdi, S., et al.
Publicado: (2020)

A comparison of epidural infusion of 0.2, 0.25, and 0.3% ropivacaine with fentanyl after unilateral total knee arthroplasty
por: Lee, Jae Ho, et al.
Publicado: (2013)

Allergic contact dermatitis masquerading as atopic dermatitis
por: Semaan, Sarah, et al.
Publicado: (2020)

Allergic Contact Dermatitis to Superglue
por: Sornakumar, L, et al.
Publicado: (2013)

Allergic contact dermatitis to slime()()
por: Pessotti, Nabila Scabine, et al.
Publicado: (2020)

Itch in Allergic Contact Dermatitis
por: Lambert, Julien
Publicado: (2021)

Nickel allergic contact dermatitis
por: Zhu, Mingang, et al.
Publicado: (2022)

Allergic Contact Dermatitis to Polycrylene®
por: Agulló, Alfredo, et al.
Publicado: (2022)

Contact Vitiligo Following Allergic Contact Dermatitis
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Nipple Eczema: A Diagnostic Challenge of Allergic Contact Dermatitis
por: Kim, Sun Kyung, et al.
Publicado: (2014)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

Neoprene Orthopaedic Supports: An Underrecognised Cause of Allergic Contact Dermatitis
por: Hawkey, S., et al.
Publicado: (2015)

Eyelid Dermatitis Caused by Allergic Contact to Acrylates in Artificial Nails
por: Moreira, Jorge, et al.
Publicado: (2017)

A Case of Autoimmune Progesterone Dermatitis Misdiagnosed as Allergic Contact Dermatitis
por: Lee, Myoung Kyu, et al.
Publicado: (2011)

Potential outstanding physical properties of novel black arsenic phosphorus As(0.25)P(0.75)/As(0.75)P(0.25) phases: a first-principles investigation
por: Liu, Fangqi, et al.
Publicado: (2022)

Benzoin Spray: Cause of Allergic Contact Dermatitis due to Its Rosin Content
por: Han, Ji Su, et al.
Publicado: (2014)

KNb(1.75)V(0.25)PS(10)
por: Yu, Jaemin, et al.
Publicado: (2011)

Treatment of angiokeratomas of Fordyce with topical rapamycin 0.25% cream
por: Bell, Katheryn A., et al.
Publicado: (2020)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Contact allergic dermatitis and periocular depigmentation after using olapatidine eye drops
por: Suchi, Smita T, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_i4kkic6ib1afjjr1no7t08ps6e